Insider Buying: Tivic Health Systems (NASDAQ:TIVC) Director Acquires 19,000 Shares of Stock

Tivic Health Systems, Inc. (NASDAQ:TIVC) Director Christina Rizopoulos Valauri purchased 19,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was bought at an average cost of $0.95 per share, with a total value of $18,050.00. Following the completion of the purchase, the director owned 19,000 shares of the company’s stock, valued at approximately $18,050. This represents a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tivic Health Systems Price Performance

Shares of TIVC stock traded down $0.02 on Thursday, reaching $0.99. 21,990 shares of the company were exchanged, compared to its average volume of 224,944. The company has a 50-day moving average of $0.94 and a 200-day moving average of $1.77. The company has a market cap of $1.75 million, a price-to-earnings ratio of -0.15 and a beta of 1.83. Tivic Health Systems, Inc. has a one year low of $0.72 and a one year high of $13.23.

Tivic Health Systems (NASDAQ:TIVC) last issued its earnings results on Wednesday, April 1st. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($408.00) by $406.97. Tivic Health Systems had a negative return on equity of 202.20% and a negative net margin of 1,557.26%.

Institutional Investors Weigh In On Tivic Health Systems

A hedge fund recently bought a new stake in Tivic Health Systems stock. Marex Group plc bought a new position in Tivic Health Systems, Inc. (NASDAQ:TIVC) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 39,283 shares of the company’s stock, valued at approximately $163,000. Marex Group plc owned about 3.64% of Tivic Health Systems as of its most recent SEC filing. Institutional investors own 4.25% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tivic Health Systems in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Tivic Health Systems Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.